Q-omics provides the consensus-scored MIR6780B profile across patient tissues and cancer cell-line models. MIR6780B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MIR6780B is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, MIR6780B RNA expression shows 7,388 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight TGCT, KIRP, and THYM as cancer lineages where MIR6780B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6780B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6780B survival associations across molecular data types. MIR6780B RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6780B RNA expression–survival associations across cancer types. High MIR6780B expression shows unfavorable associations in TGCT, LUSC, UCEC and BLCA, but favorable associations in ESCA and OV. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for MIR6780B RNA expression.
This table summarizes MIR6780B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6780B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6780B shows higher tumor expression in KIRP. The KIRP box plot shows higher MIR6780B RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .043).
This table shows molecular features associated with MIR6780B in patient tissues and cancer cell lines. In patient samples, MIR6780B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
